文献速递流行病学与生物统计医学教育与科研方法

临床研究报告——系统综述与主题综合:第1部分 历史、内容与结构、定义和术语

Clinical Study Reports-a systematic review with thematic synthesis: Part 1. History, contents and structure, definitions, and terminology.
PubMed 文献 · Trials · 2025-04-29

临床研究报告是药企向监管机构提交的标准化完整报告,1995年ICH E3文件描述了其推荐内容和结构。2015年前公众不易获取,此后部分监管机构和药企提供,但常为简略或删节版。用临床研究报告数据计算出的药物干预获益不如已发表试验报告显著,且可发现更多危害信息。本第1部分讨论其发展历史、内容与结构、定义及相关术语。

要点

  • 临床研究报告是药企向监管机构提交的标准化完整报告,包含方案、结果及其他相关信息。
  • 1995年ICH E3文件描述了其推荐内容和结构,但企业可自行选择数据呈现方式。
  • 用临床研究报告数据计算出的药物干预获益不如已发表试验报告显著,且可发现更多危害信息。

核心结论

  • 本第1部分讨论临床研究报告的发展历史、内容与结构、定义及相关术语,结论列于第2部分。

研究设计与样本

  • 系统综述与主题综合,方法见第2部分,共总结349篇各类出版物中描述的临床研究报告用途。

主要发现

  • 2015年前临床研究报告不易被公众获取,此后部分监管机构和药企提供,但常为简略或删节版。
  • 用临床研究报告数据计算出的药物干预获益不如已发表试验报告显著,且可发现更多危害信息。

关键数值与推荐

  • 1995年ICH E3文件描述了临床研究报告的推荐内容和结构,但企业可自行选择数据呈现方式。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical study reports (CSRs) are standardized full reports of the protocols, results, and other pertinent details of clinical studies that are typically submitted by pharmaceutical companies to regulatory authorities, as part of the drug approval process. Their recommended contents and structure were described in 1995 in a document of the International Conference on Harmonisation, ICH E3, although companies can choose how to present the data. Until 2015, such reports were not readily available to the public, but since then some regulatory authorities have made them available, as have some pharmaceutical companies, albeit often in abbreviated or redacted versions. The apparent benefits of pharmacological interventions are not as impressive when they are calculated using data from clinical study reports compared with published trial reports, and more information emerges about harms the interventions can cause. RESULTS: Our methods are described in Part 2 of this systematic review with thematic synthesis, in which we have summarized the uses of CSRs, as described in 349 publications of various sorts, including analyses of clinical trials, data analyses, commentaries, and official documents. We have specifically concentrated on how CSRs affect assessments of benefits, harms, and the benefit-to-harm balance, and other factors that affect it. In Part 1, we discuss the history of the development of CSRs, their contents and structure, definitions of CSRs and qualifying terms, and relevant terminology (including the availability of CSRs, data sharing systems, and transparency and confidentiality). CONCLUSIONS: Our conclusions are listed in Part 2 of this review.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Aronson JK, Onakpoya IJ. Clinical Study Reports-a systematic review with thematic synthesis: Part 1. History, contents and structure, definitions, and terminology. Trials. 2025. PMID: 40301986. doi:10.1186/s13063-024-08710-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。